Extramedullary blast crisis of chronic myelogenous leukemia as an initial presentation  by Tsukamoto, Shokichi et al.
Case report
Extramedullary blast crisis of chronic myelogenous leukemia as an
initial presentation
Shokichi Tsukamoto a, Satoshi Ota b, Chikako Ohwada a, Yusuke Takeda a,
Masahiro Takeuchi a, Emiko Sakaida a, Naomi Shimizu a,c, Koutaro Yokote d, Tohru Iseki c,
Chiaki Nakaseko a,n
a Department of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan
b Department of Pathology, Chiba University Hospital, Chiba, Japan
c Division of Transfusion Medicine and Cell Therapy, Chiba University Hospital, Chiba, Japan
d Department of Clinical Cell Biology and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan
a r t i c l e i n f o
Article history:
Received 7 April 2013
Received in revised form
25 June 2013
Accepted 17 July 2013
Available online 13 August 2013
Keywords:
Extramedullary blast crisis
Chronic myelogenous leukemia (CML)
Dasatinib
a b s t r a c t
Extramedullary blast crisis of chronic myelogenous leukemia (CML) is deﬁned as the development of
extramedullary disease caused by the inﬁltration of blasts regardless of proliferation of blasts in the bone
marrow. The onset of extramedullary blast crisis in the newly diagnosed patients is known to be
extremely rare. Here, we present a case of extramedullary blast crisis of CML as an initial presentation in
a 17-year-old female presenting with pain in the left femur tumor. This case was treated successfully
with dasatinib and allogeneic hematopoietic stem cell transplantation, with achievement of long-term
remission.
& 2013 The Authors. Published by Elsevier Ltd.
1. Case report
A 17-year-old female presented with pain in the left hip joint in
April 2010. Radiography revealed a radiolucent region at the
greater trochanter of the left femur (Fig. 1A). Computed tomogra-
phy (CT) and magnetic resonance imaging (MRI) revealed an
osteolytic tumor at the greater trochanter of the left femur
(Fig. 1B and C). Blood analyses showed an elevated white blood
cell (WBC) count of 130,200/mL; a decreased hemoglobin level of
9.4 g/dL; and an increased platelet count of 465,000/mL. The
differential leukocyte count revealed 3.4% blasts, 0.4% promyelo-
cytes, 9.2% myelocytes, 1.8% metamyelocytes, 53.6% neutrophils,
12.4% eosinophils, and 15.6% basophils. Examination of the bone
marrow showed increased cellularity due to granulocytic prolif-
eration with a maturation pattern similar to that observed in
peripheral blood, with a blast count of 6.5% and a basophil count of
5.6%. Chromosomal analyses of the bone marrow cells revealed an
t(9;22) (q34;q11.2) abnormality. The type of BCR-ABL fusion
transcripts was major BCR-ABL which led to a p210 fusion protein.
A biopsy specimen of the left femur tumor revealed extramedul-
lary blast proliferation with ﬁbrosis (Fig. 2a). An immunohisto-
chemical study demonstrated the blast cells were partially positive
for CD68 (KP-1) (Fig. 2b), CD68 (PGM-1), and myeloperoxidase,
and negative for terminal deoxynucleotidyl transferase (TdT), CD3,
CD79a, and CD34. Chromosomal analyses of the tumor cells of the
left femur also revealed a t(9;22)(q34;q11.2) abnormality. The
diagnosis was extramedullary myeloid blast crisis of chronic
myelogenous leukemia (CML).
Initially she was administered imatinib (400 mg once daily).
The WBC count in peripheral blood decreased rapidly. She
achieved a complete hematologic response within 23 days after
the initiation of imatinib therapy. Radiography revealed that the
radiolucent region at the greater trochanter of the left femur had
also improved. However, the pain in her left hip joint suddenly
worsened on the 54th day of imatinib treatment. Radiography and
CT showed that the osteolytic tumor at the greater trochanter of
the left femur had enlarged. The WBC count of peripheral blood
was 3800/mL with normal differential leukocyte count. Examina-
tion of the bone marrow showed that the bone marrow remained
in a chronic phase with a minor cytogenetic response. Mutation of
the BCR-ABL kinase domain was not detected. [18F]Fluorodeox-
yglucose positron emission tomography (FDG-PET) revealed that
abnormal uptake of FDG was limited to the tumor in the left
femur. Because of the severe pain and the risk of pathological
fracture, she was treated with involved ﬁeld radiotherapy at 30 Gy.
Contents lists available at ScienceDirect
journal homepage: www.elsevier.com/locate/lrr
Leukemia Research Reports
2213-0489 & 2013 The Authors. Published by Elsevier Ltd.
http://dx.doi.org/10.1016/j.lrr.2013.07.002
n Corresponding author. Tel./fax: þ81 43 225 6502.
E-mail addresses: chiaki-nakaseko@faculty.chiba-u.jp,
c.nakaseko@gmail.com (C. Nakaseko).
Leukemia Research Reports 2 (2013) 67–69
Open access under CC BY license.
Open access under CC BY license.
In addition, imatinib was switched to dasatinib (70 mg, twice
daily) because the residual tumor was considered to be resistant to
imatinib.
Two months from the initiation of dasatinib, abnormal FDG
uptake of the left femur tumor had disappeared. Examination of
peripheral blood and the bone marrow examination showed that a
complete cytogenetic response was achieved and a ratio of BCR-
ABL to ABL on the international scale was 0.21%. Her disease was
well controlled with dasatinib. However, we considered that
prompt allogeneic hematopoietic stem cell transplantation (allo-
HSCT) was necessary for long-term remission. Although she did
not have a sibling donor with identical human leukocyte antigens
(HLAs), her mother was HLA-1 allele-mismatched for the graft-
versus-host direction. Therefore, we performed allo-HSCT from
her mother 4 months after the diagnosis. She achieved a complete
molecular response with sensitivity of 4.5-log 1 month after
transplantation, and the osteolytic region at the greater trochanter
of the left femur gradually ossiﬁed. Considering the high preva-
lence of relapse, dasatinib maintenance was started on the 120th
day after transplantation. The dose was reduced to 20 mg once
daily, but she could not tolerate dasatinib (grade-2 malaise and
grade-3 maculopapular rash). She has been in complete remission
without the need for a tyrosine kinase inhibitor (TKI) for two and a
half years after transplantation, with excellent performance status.
1.1. Discussion
Extramedullary blast crisis of CML is deﬁned as the develop-
ment of extramedullary disease caused by the inﬁltration of blasts
regardless of proliferation of blasts in the bone marrow. Extra-
medullary blast crisis is, after a few months, almost always
followed by hematological blast crisis, so it is considered to be
an early sign of blast crisis in the bone marrow [1–3]. The
prevalence of extramedullary blast crisis has been reported to be
7–17% in patients with a blast phase (BP) [1,2,4]. From the point of
an initial presentation, the onset of extramedullary blast crisis in
the newly diagnosed patients is known to be extremely rare
because the prevalence of an accelerated phase and BP as initial
presentations has been reported to be only 5–10% in CML patients
[5].
Extramedullary blast proliferations commonly present in the
lymph node, skin, spleen, bone, or central nervous system (CNS),
but can occur anywhere, and may consist of myeloid or lymphoid
lineages. Other changes (e.g., reticulin or collagen ﬁbrosis, bone
remodeling) are more frequently seen in BP [6]. Extramedullary
blast proliferation in our patient was accompanied by ﬁbrosis,
which helped us to make a diagnosis of BP.
Considering the high prevalence of relapse in patients with BP
after allo-HSCT (r30–40%) post-transplant monitoring and pro-
phylactic/therapeutic strategies are very important. In general,
post-transplant maintenance with imatinib is well tolerated, and
serious adverse events are resolved successfully after dose reduc-
tion [7]. There have been only a few reports of post-transplant
dasatinib administration. Those studies suggested that the side
effects of dasatinib could be readily managed by dose reduction or
treatment interruption [8] and dasatinib could be useful for post-
transplant prophylactic/therapeutic strategies for patients with
CML or Philadelphia-positive acute lymphoblastic leukemia (espe-
cially for extramedullary relapse) because dasatinib can penetrate
extramedullary tissue or the CNS [9]. However, algorithms for
dosage, intervals from transplantation, and duration of application
have not been developed. Our patient could not tolerate dasatinib
after transplantation even though the dose was sufﬁciently
reduced compared with that of pre-transplant administration.
This ﬁnding was not in accordance with the results of previous
studies. Although the reason for this difference is not clear, there
may be some patients in whom the blood level of dasatinib
becomes higher than pre-transplant because of their organ
damages after transplantation. The optimal usage of post-
Fig. 1. Radiography, CT, and MRI ﬁndings at the development of extramedullary
blast crisis of CML. (A) Radiography revealed a radiolucent region, and (B) CT and
(C) MRI revealed an osteolytic tumor at the greater trochanter of the left femur.
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transplant dasatinib should be clariﬁed by the clinical trial in the
future.
The phenomenal success of therapy with TKIs in CML has
drastically changed the prognosis of this disease [10]. In contrast to
the pre-imatinib era, patients with BP are much fewer and those
with extramedullary blast crisis are even fewer. However, the
initial onset of BP will not change in the future; there is still a
chance to encounter an extramedullary blast crisis as an initial
presentation. The results of this case study will raise awareness
and offer suggestions for management of this rare manifestation
of CML.
References
[1] Inverardi D, Lazzarino M, Morra E, Bernasconi P, Merante S, Canevari A, et al.
Extramedullary disease in Ph’-positive chronic myelogenous leukemia: fre-
quency, clinical features and prognostic signiﬁcance. Haematologica
1990;75:146–8.
[2] Terjanian T, Kantarjian H, Keating M, Talpaz M, McCredie K, Freireich EJ.
Clinical and prognostic features of patients with Philadelphia chromosome-
positive chronic myelogenous leukemia and extramedullary disease. Cancer
1987;59:297–300.
[3] Kantarjian HM, Keating MJ, Talpaz M, Walters RS, Smith TL, Cork A, et al.
Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients.
American Journal of Medicine 1987;83:445–54.
[4] Specchia G, Palumbo G, Pastore D, Mininni D, Mestice A, Liso V. Extramedul-
lary blast crisis in chronic myeloid leukemia. Leukemia Research
1996;20:905–8.
[5] Faderl S, Talpaz M, Estrov Z, Kantarjian HM. Chronic myelogenous leukemia:
biology and therapy. Annals of Internal Medicine 1999;131:207–19.
[6] Cotta CV, Bueso-Ramos CE. New insights into the pathobiology and treatment
of chronic myelogenous leukemia. Annals of Diagnostic Pathology
2007;11:68–78.
[7] Klyuchnikov E, Kroger N, Brummendorf TH, Wiedemann B, Zander AR, Bacher
U. Current status and perspectives of tyrosine kinase inhibitor treatment in
the posttransplant period in patients with chronic myelogenous leukemia
(CML). Biology of Blood and Marrow Transplantation 2010;16:301–10.
[8] Klyuchnikov E, Schafhausen P, Kroger N, Brummendorf TH, Osanmaz O,
Asenova S, et al. Second-generation tyrosine kinase inhibitors in the post-
transplant period in patients with chronic myeloid leukemia or Philadelphia-
positive acute lymphoblastic leukemia. Acta Haematologica 2009;122:6–10.
[9] Alimena G, Breccia M, Latagliata R, Grammatico S, Matturro A, Capria S, et al.
Dasatinib in the management of lymphoid blast crisis of Philadelphia-positive
chronic myeloid leukemia with multiple extra-medullary and intracranial
localizations. Leukemia Research 2009;33:e134–6.
[10] Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N,
et al. Five-year follow-up of patients receiving imatinib for chronic myeloid
leukemia. New England Journal of Medicine 2006;355:2408–17.
Fig. 2. A biopsy specimen of the left femur tumor. (a) Hematoxylin and eosin staining, high-power ﬁeld. Extramedullary blast proliferation with ﬁbrosis was seen.
(b) Immunohistochemical staining for CD68 (KP-1), high-power ﬁeld. The blast cells were partially positive for CD68 (KP-1).
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